CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could ... who led the trial, said the findings “constitute a significant step forward in the future management ...
The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
Late-stage trial data of CagriSema ... result in a hit of $1.26 billion this year from debt financing. Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback